Oncogene-like addiction to aneuploidy in human cancers

Most cancers exhibit aneuploidy, but its functional significance in tumor development is controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a set of chromosome engineering tools that allow us to eliminate specific aneuploidies from cancer genomes. U...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Science (American Association for the Advancement of Science) 2023-08, Vol.381 (6660), p.eadg4521-eadg4521
Hauptverfasser: Girish, Vishruth, Lakhani, Asad A, Thompson, Sarah L, Scaduto, Christine M, Brown, Leanne M, Hagenson, Ryan A, Sausville, Erin L, Mendelson, Brianna E, Kandikuppa, Pranav K, Lukow, Devon A, Yuan, Monet Lou, Stevens, Eric C, Lee, Sophia N, Schukken, Klaske M, Akalu, Saron M, Vasudevan, Anand, Zou, Charles, Salovska, Barbora, Li, Wenxue, Smith, Joan C, Taylor, Alison M, Martienssen, Robert A, Liu, Yansheng, Sun, Ruping, Sheltzer, Jason M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Most cancers exhibit aneuploidy, but its functional significance in tumor development is controversial. Here, we describe ReDACT (Restoring Disomy in Aneuploid cells using CRISPR Targeting), a set of chromosome engineering tools that allow us to eliminate specific aneuploidies from cancer genomes. Using ReDACT, we created a panel of isogenic cells that have or lack common aneuploidies, and we demonstrate that trisomy of chromosome 1q is required for malignant growth in cancers harboring this alteration. Mechanistically, gaining chromosome 1q increases the expression of and suppresses p53 signaling, and we show that mutations are mutually exclusive with 1q aneuploidy in human cancers. Thus, tumor cells can be dependent on specific aneuploidies, raising the possibility that these "aneuploidy addictions" could be targeted as a therapeutic strategy.
ISSN:0036-8075
1095-9203
1095-9203
DOI:10.1126/science.adg4521